In general news, the Bashar al-Assad Syrian government provoked the U.S. again by gassing civilians, causing Trump to blame Russia for backing the regime. Both South Korea and Brazil sent former presidents to prison for corruption. China claimed that it would increase tariffs in U.S. products, and President Trump plans to send the military to the Mexican border.
In healthcare business news, the holiday week created a slow news cycle. Novo Nordisk (NVO) plans to license EpiDestiny’s sickle cell disease program. Also, the court saga over JNJ’s liability for cancer caused by baby powder continued, as a court ruled against JNJ.
On the data front, Incyte’s (INCY) immunotherapy failed in a melanoma trial that paired it with Merck’s (MRK) Keytruda.
From the FDA, Alkermes (ALKS) was rejected with the application for their depression combo-pill.